-
Mashup Score: 14The expansion of human T-bethighCD21low B cells is T cell dependent - 8 month(s) ago
T cell–derived IFNγ and CD40L/IL-21R signals are crucial for the differentiation of human T-bethighCD21low B cells.
Source: www.science.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 61Unveiling the B cell receptor structure - 8 month(s) ago
Molecular structures provide a road map for understanding and controlling B cell receptor activation
Source: www.science.orgCategories: Future of Medicine, Latest HeadlinesTweet-
Last year, two Science papers revealed the structures of the #Bcell receptor complex. The results are likely to inform the development of highly effective vaccines, therapies for cancers, and treatments for autoimmune diseases. https://t.co/B5byVNfGJc #ScienceMagArchives https://t.co/yRc7ZCUn5E
-
-
Mashup Score: 70Unveiling the B cell receptor structure - 8 month(s) ago
Molecular structures provide a road map for understanding and controlling B cell receptor activation
Source: www.science.orgCategories: Future of Medicine, Latest HeadlinesTweet-
Last year, two Science papers revealed the structures of the #Bcell receptor complex. The results are likely to inform the development of highly effective vaccines, therapies for cancers, and treatments for autoimmune diseases. https://t.co/5jBefb1ekK #ScienceMagArchives https://t.co/XMhPFri3r7
-
-
Mashup Score: 1Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda - 9 month(s) ago
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda By Professor Nagesh Kalakonda Thank you for this opportunity to talk about the L-MIND study. The study itself was initiated in 2016 and targeted relapsed refractory patients with diffuse large B-cell lymphoma. It was …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⚡ Prof. Kalakonda @LivUni @AACR shares the final results of the Five-Year Safety and Efficacy Study (Phase II L-MIND) involving #Tafasitamab for DLBCL. Impressive 57.5% overall response rate. #FDA approved! #Bcell #Lymphoma @OncoAlert 🎥 Watch [video] https://t.co/GwIpy6wJ50 https://t.co/QsMXzc5uC9
-
-
Mashup Score: 0Researchers find weaker immune response to viral infections in children with mitochondrial disorders - 10 month(s) ago
One of the first human studies on how mitochondrial function impacts immune cells to guide future treatments.
Categories: Healthcare Professionals, Latest HeadlinesTweet-
Researchers find weaker immune response to viral infections in children with #mitochondrialdisorders https://t.co/wOSesRkPAA @NIH Primary #oxidativephosphorylation defects lead to perturbations in the human #Bcell repertoire https://t.co/IYDvnznpm8 #RNASeq #Mito #mitochondria… https://t.co/fhSsEF8g3v
-
-
Mashup Score: 4Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response - Nature Communications - 11 month(s) ago
Protective immunity against SARS-CoV-2 relies on both antibodies and a T cell dependent response, however, direct experimental evidence for the contribution of cellular immunity is limited. Here authors present a mouse model that is susceptible to SARS-CoV-2 and lacks B cells to demonstrate the emergence of efficient cellular immune response against SARS-CoV-2 upon vaccination or viral challenge.
Source: NatureCategories: Infectious Disease, Latest HeadlinesTweet-
💡 Published in @NatureComms, researchers showed that the mRNA vaccine BNT162b2 induced robust protective #immunity 🛡️ in K18- human angiotensin-converting enzyme 2 transgenic #Bcell deficient mice. https://t.co/qCK59GG39u https://t.co/FGq3U2d97S
-
-
Mashup Score: 0ATRA, Crenigacestat Synergistically Augment BCMA on MM, BCMA-CAR T-Cell Efficacy | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination April 4, 2023 Katie Robinson is a medical writer based in New York. In a pre-clinical study, all-trans retinoic acid (ATRA) treatment, alone or in combination with crenigacestat, led to enhanced B-cell…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Treatment with all-trans retinoic acid, alone or in combination with #crenigacestat, leads to enhanced #Bcell maturation antigen (#BCMA) expression on #multiplemyeloma (MM) cells, increasing the reactivity of BCMA-CAR #Tcells https://t.co/FJyXAAk2qA
-
-
Mashup Score: 3Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma - 1 year(s) ago
Single-cell and spatial profiling of tumor-infiltrating B and plasma cells in early-stage lung adenocarcinoma (LUAD) highlights previously unappreciated roles of these cells in the LUAD ecosystem and immunotherapy response.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Heading to the #AACR23 session on #BCell Responses? ICYMI: The #SingleCell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma, by speaker @IamLinghua. https://t.co/xAGuWadQmg #lcsm https://t.co/iqgygWVrmd
-
-
Mashup Score: 0
Key Points. Short-term combination costimulatory blockade induces B cell tolerance in NZB/W mice.Combination treatment modulates CD4 T cell metabolism in aged N
Categories: Allergy-Immunology, Latest HeadlinesTweet-
Long-lived suppressive effects of dual #costimulatory blockade on both T & B cell #metabolism & changes in GC B cell signaling that may contribute to #Bcell #tolerance | from previous #JI_editor @DavidsonAnne @NorthwellHealth 👉 https://t.co/WgZDLZ4PL3 https://t.co/KjtWzMDBkP
-
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - Could Zanubrutinib Be an Alternative to Patients With BTK Inhibitor–Intolerant B-Cell Malignancies? - 1 year(s) ago
By: Vanessa A. Carter, BS Posted: Wednesday, February 8, 2023 Mazyar Shadman, MD, of Fred Hutchinson Cancer Center, Seattle, and colleagues aimed to evaluate whether zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—might lengthen treatment duration by reducing treatment-related discontinuations…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Could Zanubrutinib Be an Alternative to Patients With BTK Inhibitor–Intolerant #Bcell Malignancies? https://t.co/BygD480g1s #JNCCN360 #lymsm https://t.co/cPwyoZqKPa
-
A 2021 @UniFreiburg study detailed the development of a #Bcell subset that expands when the adaptive immune system is chronically activated, and is frequently implicated in an array of #autoimmune diseases. Learn more: https://t.co/vcxXzzdCVP #WeekendReads https://t.co/Tj6GYAxvee